Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.30 |
| ▸ | BCL2 | P10415 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthine SCHEMBL918381 | 0.79 | MEN1 (0.34) | LMNAMEN1KMT2ACSNK2A2RAB9A | |
| Xanthine SCHEMBL9443796 | 0.79 | MEN1 (0.34) | LMNAMEN1KMT2ACSNK2A2RAB9A | |
| SCHEMBL7019371 | 0.79 | PDPK1 (0.36) | PDPK1MEN1KMT2ACSNK2A2RAB9A | |
| Ammonia Solution, Strong SCHEMBL16871771 | 0.78 | PDPK1 (0.35) | PDPK1PARP1 | |
| SCHEMBL130810 | 0.77 | XDH (0.38) | PDPK1LMNAMEN1KMT2ACSNK2A2 | |
| Isoguanine SCHEMBL887740 | 0.76 | PARP1 (0.36) | PDPK1LMNAMEN1KMT2ACSNK2A2 | |
| SCHEMBL218972 | 0.76 | LMNA (0.33) | LMNAMEN1KMT2ACSNK2A2RAB9A | |
| SCHEMBL16146330 | 0.76 | CSNK2A1 (0.33) | LMNAMEN1KMT2ACSNK2A2RAB9A | |
| SCHEMBL2938699 | 0.76 | PDPK1 (0.37) | PDPK1LMNA | |
| SCHEMBL9925954 | 0.76 | PDPK1 (0.34) | PDPK1DYRK1APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| US-9718815-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170050987-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-02-23 | — | — | US | disclosed |
| US-9434746-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150126506-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8969363-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8940752-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-01-27 | — | — | US | disclosed |
| WO-2013012915-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
| WO-1992020816-A1 | DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF | YALE UNIVERSITY (US) | 1992-11-26 | — | — | WO | disclosed |
| WO-1990006312-A1 | 2',3'-DIDEOXYRIBOFURANOSIDES AND PROCESS FOR PRODUCING THEM | INSTITUT FÜR MOLEKULARBIOLOGIE UND ANALYTIK (IMA) GMBH (DE) | 1990-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | PDPK1 3/4885LMNA 1935/4885MEN1 3690/4885 |
| US-20150126506-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PDPK1 10/4885LMNA 1475/4885MEN1 1386/4885 |
| US-20170050987-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PDPK1 18/4885LMNA 4728/4885MEN1 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.